FUNDAMENTALS · Fundamentals · US Healthcare

Cardio Diagnostics Holdings (CDIO) Fundamentals 2026 — Revenue Analysis | SniperIQ

Cardio Diagnostics Holdings (CDIO) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at

.72 on the NASDAQ. This SniperIQ fundamentals page covers Cardio Diagnostics Holdings's valuation, profitability (net margin -40152.5%), revenue (
4,825 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$4M
Net Margin-40152.5%
Revenue (FY25)
4,825

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Cardio Diagnostics Holdings's market cap?

Cardio Diagnostics Holdings (CDIO) has a market capitalization of approximately $4M, trading at

.72 on the NASDAQ. Market cap moves with the live share price.

What is Cardio Diagnostics Holdings's P/E ratio?

Cardio Diagnostics Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Cardio Diagnostics Holdings?

Cardio Diagnostics Holdings runs a net profit margin of -40152.5%, a gross margin of -471.4%, and an operating margin of -40074.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Cardio Diagnostics Holdings generate?

Cardio Diagnostics Holdings reported revenue of

4,825 for fiscal year 2025, with net income of -$6M and earnings per share (EPS) of -3.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Cardio Diagnostics Holdings pay a dividend?

Cardio Diagnostics Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Cardio Diagnostics Holdings financially healthy?

Cardio Diagnostics Holdings carries a debt-to-equity ratio of 0.06x and a current ratio of 15.76x, with a market beta of 2.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Cardio Diagnostics Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cardio Diagnostics Holdings (CDIO) the key facts are: market cap $4M, revenue

4,825, 52-week range 0.97-7.91. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Cardio Diagnostics Holdings's full fundamentals live

Get Cardio Diagnostics Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: GT Biopharma (GTBP) fundamentals · MetaVia (MTVA) fundamentals · Cellyan Biotechnology (HKPD) fundamentals · Pasithea Therapeutics (KTTA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons